Cancer Recovery & Support
Recovering from cancer is more than overcoming the disease—it’s about rebuilding your life. At JCRC-ABT CellGene Innovations, we offer regenerative therapies, including stem cell treatments and immunotherapy, to aid recovery post-chemotherapy and radiation, repair tissue damage, and promote long-term health and resilience.
What Is Cancer Recovery & Support?
Cancer recovery and support focus on helping patients regain strength and vitality after treatments like chemotherapy, radiation, or surgery. These traditional therapies, while effective in targeting cancer cells, can leave patients dealing with fatigue, weakened immunity, and damaged tissues.
Our recovery programs combine advanced regenerative medicine with holistic care, addressing both the physical and emotional challenges of cancer recovery. This approach helps patients rebuild their health and regain control of their lives.
Benefits of Our Treatments for Cancer Recovery
Repairs Tissue Damage
MSC-based therapies promote the repair of tissues damaged by radiation or chemotherapy, aiding in faster physical recovery.
Strengthens Immune Function
Immunotherapy enhances the body’s natural defenses, helping reduce the risk of infections and supporting recovery.
Boosts Energy and Vitality
Regenerative treatments improve cellular function, combating fatigue and restoring energy levels for a healthier post-cancer life.
Promotes Long-Term Wellness
Modern therapies help reduce lingering side effects and promote resilience, enabling patients to focus on their future.
Why Choose Us?
At JCRC-ABT CellGene Innovations, we are dedicated to helping cancer survivors rebuild their strength and embrace a healthier future. Our personalized recovery plans and advanced therapies ensure holistic care tailored to your journey.
1. Who can benefit from cancer recovery and support programs?
We specialize in treating sickle cell disease, anemia, leukemia, and other hereditary or acquired blood disorders.
2. How do bone marrow transplants work for blood disorders?
Our programs are designed for patients recovering from chemotherapy, radiation, surgery, or other cancer treatments.
3. Can these therapies prevent cancer recurrence?
While no treatment guarantees prevention, therapies like immunotherapy strengthen the immune system, reducing risk factors associated with recurrence.
4. How soon can I start recovery treatments after cancer therapy?
Patients can begin once cleared by their oncology team, ensuring treatments align with their overall recovery plan.
5. Are these treatments safe for all cancer survivors?
Yes, our therapies are designed to be safe and effective for a wide range of patients, including those with complex recovery needs.
Achievements
Case Studies
Acute Lymphoblastic Leukemia (ALL)
A study in Blood highlighted the success of CAR-T cell therapy (tisagenlecleucel) in pediatric and young adult patients with relapsed/refractory ALL. Over 80% achieved complete remission within one month of treatment, with sustained responses observed in more than 50% at 12 months.
Non-Small Cell Lung Cancer (NSCLC)
Research published in Nature showed that combining nivolumab (anti-PD-1) with ipilimumab (anti-CTLA-4) significantly improved progression-free survival in advanced NSCLC patients. The combination therapy demonstrated a 36% reduction in disease progression risk compared to chemotherapy.
Melanoma
A pivotal study in The New England Journal of Medicine demonstrated the efficacy of immune checkpoint inhibitors like pembrolizumab (anti-PD-1) in advanced melanoma. Patients experienced a 5-year overall survival rate of 43%, with durable tumor regression and manageable side effects, marking a breakthrough in melanoma treatment.
Cystic Fibrosis
A trial targeting CFTR gene mutations delivered via aerosolized vectors showed improved pulmonary function in patients with cystic fibrosis. Published in The Lancet Respiratory Medicine, the therapy reduced hospitalizations and improved quality of life metrics over 12 months.
Hemophilia B
Gene therapy using an AAV vector to deliver the FIX gene resulted in sustained Factor IX production in patients. A landmark study in Blood reported a significant reduction in bleeding episodes and factor replacement therapy use, lasting up to 5 years.
Leber’s Congenital Amaurosis (LCA)
The gene therapy Luxturna restored partial vision in patients with RPE65 gene mutations. Clinical trials demonstrated improved light sensitivity and navigation abilities, with effects persisting for over three years.
